A single, 24-minute IV infusion of ferric derisomaltose (1000 mg) rapidly elevates maternal hemoglobin levels and enhances infant iron reserves while reducing postpartum depression and fatigue risks.
Iron deficiency anemia (IDA) during pregnancy can compromise maternal well-being and neonatal iron status. Although oral iron is commonly utilized, poor adherence can restrict treatment success, while some intravenous iron formulations require multiple infusions. A study, led by Ashley E. Benson et al., explored whether a single dose of ferric derisomaltose (FDI) yields an effective and convenient alternative during pregnancy.
Conducted between January 2024 and July 2025, the prospective, single-arm interventional trial assessed the safety and efficacy of a single 1,000 mg IV dose of FDI administered during the second or third trimester. The mean infusion duration was 24 minutes. Of the 78 participants enrolled, 75 received treatment. The key endpoint ascertained was a hemoglobin (Hb) increase of at least 1 g/dL. Secondary endpoints included other hematological parameters, patient-reported quality of life, safety, and maternal and neonatal outcomes.
Key findings
Minor infusion-linked symptoms were uncommon and self-limited. These encompassed chest tightness (6.7%), flushing (5.3%), mild shortness of breath (4%), urticaria (2.7%) and rash (1.3%). Notably, 2 subjects (2.6%) did not complete the infusion because of an infusion reaction. These results highlight single-dose IV FDA as a valuable option for tackling late-stage maternal IDA, though larger trials remain prudent to confirm comparative superiority.
American Journal of Hematology
Efficacy of Single-Dose Intravenous Ferric Derisomaltose for Iron Deficiency Anemia in Pregnancy
Ashley E. Benson et al.
Comments (0)